Showing 1 - 20 results of 47 for search 'Ulrike Bacher', query time: 0.06s Refine Results
  1. 1
    The Evolving Treatment Landscape of AML

    The Evolving Treatment Landscape of AML by Sabine Blum, Ulrike Bacher, Thomas Pabst

    Published 2022-03-01
    Get full text
    Article
  2. 2
    Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia

    Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia by Katja Seipel, Karin Schmitter, Ulrike Bacher, Thomas Pabst

    Published 2019-11-01
    Get full text
    Article
  3. 3
    When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis

    When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis by Nicolas Bonadies, Alicia Rovó, Naomi Porret, Ulrike Bacher

    Published 2021-03-01
    Get full text
    Article
  4. 4
    BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

    BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia by Katja Seipel, Basil Kopp, Ulrike Bacher, Thomas Pabst

    Published 2021-02-01
    Get full text
    Article
  5. 5
    HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

    HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia by Katja Seipel, Scarlett Kohler, Ulrike Bacher, Thomas Pabst

    Published 2023-08-01
    Get full text
    Article
  6. 6
    Autologous Transplantation for Older Adults with AML

    Autologous Transplantation for Older Adults with AML by Beatrice U. Mueller, Katja Seipel, Ulrike Bacher, Thomas Pabst

    Published 2018-09-01
    Get full text
    Article
  7. 7
    Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia

    Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia by Katja Seipel, Yvo Brügger, Harpreet Mandhair, Ulrike Bacher, Thomas Pabst

    Published 2022-10-01
    Get full text
    Article
  8. 8
    Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia

    Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia by Katja Seipel, Carolyn Graber, Laura Flückiger, Ulrike Bacher, Thomas Pabst

    Published 2021-07-01
    Get full text
    Article
  9. 9
    (2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia

    (2<i>R</i>,3<i>S</i>)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia by Jeffrey R. Idle, Katja Seipel, Ulrike Bacher, Thomas Pabst, Diren Beyoğlu

    Published 2020-10-01
    Get full text
    Article
  10. 10
    BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study

    BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study by Tanja Stoffel, Ulrike Bacher, Yara Banz, Michael Daskalakis, Urban Novak, Thomas Pabst

    Published 2022-06-01
    Get full text
    Article
  11. 11
    Systemic mastocytosis with an associated hematological neoplasms: One or two entities?

    Systemic mastocytosis with an associated hematological neoplasms: One or two entities? by Linet Njue, Naomi Porret, Michaela Fux, Ulrike Bacher, Yara Banz, Alicia Rovó

    Published 2020-07-01
    Get full text
    Article
  12. 12
    Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

    Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy by Katja Seipel, Mariesol Abbühl, Ulrike Bacher, Henning Nilius, Michael Daskalakis, Thomas Pabst

    Published 2023-06-01
    Get full text
    Article
  13. 13
    sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma

    sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma by Katja Seipel, Naomi Porret, Gertrud Wiedemann, Barbara Jeker, Vera Ulrike Bacher, Thomas Pabst

    Published 2022-03-01
    Get full text
    Article
  14. 14
    Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML

    Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML by Alexander D. Heini, Naomi Porret, Reinhard Zenhaeusern, Annette Winkler, Ulrike Bacher, Thomas Pabst

    Published 2021-06-01
    Get full text
    Article
  15. 15
    Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients

    Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients by Evgenyi Shumilov, Urban Novak, Barbara Jeker, Behrouz Mansouri Taleghani, Ulrike Bacher, Thomas Pabst

    Published 2019-04-01
    Get full text
    Article
  16. 16
    Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma

    Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma by Katja Seipel, Michèle Frey, Henning Nilius, Dilara Akhoundova, Yara Banz, Ulrike Bacher, Thomas Pabst

    Published 2023-12-01
    Get full text
    Article
  17. 17
    OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT

    OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT by Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri Taleghani, Urban Novak, Thomas Pabst

    Published 2023-04-01
    Get full text
    Article
  18. 18
    Blinatumomab in Relapsed/Refractory Burkitt Lymphoma

    Blinatumomab in Relapsed/Refractory Burkitt Lymphoma by Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst

    Published 2022-12-01
    Get full text
    Article
  19. 19
    Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

    Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy by Vera Rentsch, Katja Seipel, Yara Banz, Gertrud Wiedemann, Naomi Porret, Ulrike Bacher, Thomas Pabst

    Published 2022-05-01
    Get full text
    Article
  20. 20
    BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

    BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia by Alexander D. Heini, Philipp Beck, Ulrike Bacher, Katja Seipel, Thilo Zander, Michael Daskalakis, Thomas Pabst

    Published 2023-03-01
    Get full text
    Article

Search Tools: